Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial

Skyhawk Therapeutics’ RNA-splicing candidate for Huntington’s disease improved patients’ symptoms in an early stage-trial, the company said, as it moves to pivotal development. The therapy, called SKY-0515, led to a 1.59-point improvement on a disease ...